Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1970 1
1973 6
1974 3
1975 2
1978 2
1979 1
1982 2
1983 5
1984 2
1985 5
1986 2
1987 1
1988 3
1991 6
1992 1
1993 2
1994 4
1995 9
1996 4
1997 1
1998 6
1999 7
2000 4
2001 2
2002 8
2003 6
2004 11
2005 6
2006 11
2007 9
2008 11
2009 16
2010 11
2011 17
2012 32
2013 17
2014 26
2015 20
2016 19
2017 29
2018 21
2019 30
2020 35
2021 41
2022 30
2023 22
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

450 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators. Weber J, et al. N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10. N Engl J Med. 2017. PMID: 28891423 Free article. Clinical Trial.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C; EORTC Melanoma Group. Eggermont AMM, et al. Lancet Oncol. 2021 May;22(5):643-654. doi: 10.1016/S1470-2045(21)00065-6. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857412 Clinical Trial.
Vanishing basal ganglia in ATP1A3-related polymicrogyria.
Ogawa E, Sakaguchi Y, Enokizono M, Yoshihashi H, Yamada M, Suzuki H, Kosaki K, Miyama S, Takenouchi T. Ogawa E, et al. Among authors: takenouchi t. Am J Med Genet A. 2022 Feb;188(2):665-667. doi: 10.1002/ajmg.a.62531. Epub 2021 Oct 11. Am J Med Genet A. 2022. PMID: 34633143 No abstract available.
Protection against neurodegenerative disease on Earth and in space.
Takamatsu Y, Koike W, Takenouchi T, Sugama S, Wei J, Waragai M, Sekiyama K, Hashimoto M. Takamatsu Y, et al. Among authors: takenouchi t. NPJ Microgravity. 2016 Apr 7;2:16013. doi: 10.1038/npjmgrav.2016.13. eCollection 2016. NPJ Microgravity. 2016. PMID: 28725728 Free PMC article.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Eggermont AMM; EORTC Melanoma Group. Bottomley A, et al. Lancet Oncol. 2021 May;22(5):655-664. doi: 10.1016/S1470-2045(21)00081-4. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857414 Clinical Trial.
Importance of adiponectin activity in the pathogenesis of Alzheimer's disease.
Waragai M, Ho G, Takamatsu Y, Sekiyama K, Sugama S, Takenouchi T, Masliah E, Hashimoto M. Waragai M, et al. Among authors: takenouchi t. Ann Clin Transl Neurol. 2017 Jul 11;4(8):591-600. doi: 10.1002/acn3.436. eCollection 2017 Aug. Ann Clin Transl Neurol. 2017. PMID: 28812049 Free PMC article. Review.
Gas biology: tiny molecules controlling metabolic systems.
Kajimura M, Nakanishi T, Takenouchi T, Morikawa T, Hishiki T, Yukutake Y, Suematsu M. Kajimura M, et al. Among authors: takenouchi t. Respir Physiol Neurobiol. 2012 Nov 15;184(2):139-48. doi: 10.1016/j.resp.2012.03.016. Epub 2012 Mar 30. Respir Physiol Neurobiol. 2012. PMID: 22516267 Free article. Review.
450 results